Corbus Pharmaceuticals Holdings (CRBP) Share-based Compensation (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Share-based Compensation of $8.3 million for Q3 2025, up 369940.12% year-over-year from N/an in Q3 2024, and up 530930.07% quarter-over-quarter from $1563.0 in Q2 2025.
Corbus Pharmaceuticals Holdings (CRBP) Share-based Compensation (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Share-based Compensation history runs 13 years deep, the most recent figure standing at $8.3 million for Q3 2025.
- In Q3 2025, Share-based Compensation rose 369940.12% year-over-year to $8.3 million; the TTM figure through Sep 2025 stood at $8.3 million (up 365.11% YoY), while the FY2024 annual figure was $6.1 million, up 77.09% from the prior year.
- Share-based Compensation for Q3 2025 stood at $8.3 million, up from $1563.0 in the prior quarter.
- The five-year high for Share-based Compensation was $8.3 million in Q3 2025, with the low at $1288.0 in Q2 2024.
- The 5-year median for Share-based Compensation is $1.3 million (2022), against an average of $1.6 million.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation plunged 99.84% in 2024, then surged 369940.12% in 2025.
- Corbus Pharmaceuticals Holdings' Share-based Compensation stood at $1.8 million in 2021, then slipped by 29.23% to $1.3 million in 2022, then sank by 37.05% to $799000.0 in 2023, then soared by 104.26% to $1.6 million in 2024, then jumped by 408.58% to $8.3 million in 2025.
- Business Quant data shows CRBP's Share-based Compensation at $8.3 million in Q3 2025, $1563.0 in Q2 2025, and $1.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | - |
| 10 | Corbus Pharmaceuticals Holdings | 122.15 Mn | -41.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 8.30 Mn |
| Sep 30, 2025 | 8.30 Mn |
| Jun 30, 2025 | 1,563.00 |
| Jun 30, 2025 | 1,563.00 |
| Mar 31, 2025 | 1.71 Mn |
| Mar 31, 2025 | 1.71 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Sep 30, 2024 | 2,243.00 |
| Sep 30, 2024 | 2,243.00 |
| Jun 30, 2024 | 1,288.00 |
| Jun 30, 2024 | 1,288.00 |
| Mar 31, 2024 | 982,000.00 |
| Mar 31, 2024 | 982,000.00 |
| Dec 31, 2023 | 799,000.00 |
| Dec 31, 2023 | 799,000.00 |
| Sep 30, 2023 | 821,000.00 |
| Sep 30, 2023 | 821,000.00 |
| Jun 30, 2023 | 823,000.00 |
| Jun 30, 2023 | 823,000.00 |